Escitalopram: Clinical Studies & Trial Evidence
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used as a first-line treatment for depression, anxiety disorders, OCD, and PTSD.
SSRIs have the most comprehensively studied evidence base in psychiatric pharmacology, with landmark network meta-analyses confirming superiority over placebo across multiple anxiety and depressive disorders.
Key Clinical Trials
Cipriani et al. — Antidepressant Network Meta-Analysis
2018All SSRIs more effective than placebo for MDD. NNT ≈ 7 for response. Escitalopram and sertraline showed best combination of efficacy and acceptability.
Lancet 2018; 391(10128): 1357–1366
STAR*D — Sequenced Treatment Alternatives to Relieve Depression
2006~33% remission with initial citalopram treatment. Sequential switching strategies effective after initial non-response. Real-world effectiveness of SSRI-first strategy validated.
Am J Psychiatry 2006; 163(11): 1905–1917
Bandelow et al. — Meta-analysis of Anxiety Pharmacotherapy
2015SSRIs and SNRIs most effective pharmacotherapy for GAD, PTSD, OCD, and panic disorder. NNT ≈ 4–8 across anxiety subtypes.
World J Biol Psychiatry 2015; 16(3): 149–184
Walkup et al. — CAMS Trial (Child/Adolescent Anxiety)
2008Sertraline + CBT combination therapy most effective (80.7% response). Sertraline alone superior to placebo (54.9% vs 23.7%). Established SSRI use in paediatric anxiety.
NEJM 2008; 359(26): 2753–2766
Numbers Needed to Treat (NNT / NNH)
Depression response: NNT ≈ 7 (Cipriani 2018). Depression remission: NNT ≈ 9. GAD response: NNT ≈ 5. OCD response (≥25% Y-BOCS reduction): NNT ≈ 5. Panic disorder panic-free: NNT ≈ 6.
Systematic Reviews & Meta-Analyses
- •Cipriani et al. (Lancet 2018) — 522 trials, all SSRIs superior to placebo for MDD
- •Cochrane review — fluoxetine for adults with MDD: RR 1.27 vs placebo for response
- •Bandelow et al. (WJ Bio Psych 2015) — SSRIs/SNRIs highest-quality evidence for anxiety
- •Krogh et al. (Cochrane 2017) — sertraline for MDD: NNT 8 for remission
Guideline Endorsements
- ✓NICE CG90/CG113 (updated 2022) — SSRIs first-line for MDD, GAD, PTSD, panic disorder, OCD
- ✓APA Clinical Practice Guidelines (2010, updated) — SSRIs/SNRIs first-line for anxiety disorders
- ✓CANMAT 2016 — SSRIs first-line for MDD, Class A recommendation
- ✓BAP Guidelines (2015) — sertraline or escitalopram preferred for initial MDD treatment
- ✓WHO Essential Medicines List — fluoxetine included as essential medicine
Comparative Effectiveness
- ↔SSRIs vs TCAs: equivalent efficacy for depression; SSRIs have superior tolerability and safety in overdose
- ↔SSRIs vs SNRIs: broadly comparable; SNRIs may have marginal advantage in severe depression
- ↔SSRIs vs benzodiazepines: SSRIs preferred long-term for anxiety; no dependence risk
- ↔Escitalopram and sertraline: best efficacy-tolerability balance in head-to-head comparisons (Cipriani 2018)
Key Safety Signals
SSRI discontinuation syndrome in 20–40% of patients stopping abruptly. Black-box warning for suicidality in children/adolescents (FDA 2004) — requires clinical monitoring. Serotonin syndrome risk with co-administration of serotonergic drugs (rare but serious). QTc prolongation with citalopram/escitalopram above dose limits. SIADH in elderly. Upper GI bleeding risk (especially with NSAIDs or anticoagulants).
Evidence Limitations
- !Publication bias: negative trials underrepresented in SSRI literature
- !Short follow-up: most pivotal trials 6–12 weeks; long-term data less robust
- !Heterogeneous populations: response rates vary significantly by severity and subtype
- !Placebo response high in mild depression — benefit over placebo largest in moderate-severe MDD
Conditions Treated with Escitalopram
Questions about Escitalopram?
Our AI Symptom Checker analyses your symptoms, suggests diagnoses, and identifies relevant medications — including clinical evidence summaries.
Use AI Symptom Checker →